Qumra Capital

Qumra Capital occupies a specific and increasingly important position in the Israeli venture ecosystem: the late-stage growth fund that takes companies from product-market fit to global scale. Founded in 2014 in Tel Aviv with approximately eight hundred million dollars under management, Qumra was the first Israeli venture firm to focus exclusively on the late-stage Israeli market, and that specialization shows in how the team underwrites and supports its companies. For physician-founders building AI tools, Qumra is not a discovery-stage partner; it is the firm to know when a healthcare AI company has crossed into meaningful revenue, holds enterprise references, and is preparing for the kind of capital-efficient global expansion that defines a category leader.

The investment thesis is disciplined and pattern-driven. Qumra concentrates on Series B, Series C, and growth rounds in companies with proven product-market fit and significant revenue, typically leading or co-leading rounds of twenty to sixty million dollars with Qumra checks of fifteen to thirty million. The firm’s sectors are cybersecurity, fintech, artificial intelligence, and digital health, with the AI lens applied across the others. Within healthcare and AI, Qumra looks for companies with clinical and commercial validation, durable enterprise contracts or consumer revenue, and a credible path to global expansion from the Israeli base. The firm avoids early-stage clinical risk and pre-revenue stories; it concentrates capital where the question has shifted from whether the product works to whether the company can scale. Founders should expect commercial diligence focused on retention, expansion, sales efficiency, and unit economics, with technical diligence in support rather than the lead.

Qumra’s digital health portfolio is small but reads as deliberate. Tyto Care, the home telehealth examination platform that connects consumers with clinicians for remote diagnosis, illustrates the firm’s preference for companies pairing hardware, software, and clinical workflows at consumer scale. Talkspace, the digital mental health company that powers programs including the New York City Department of Health and Mental Hygiene’s free therapy initiative for teens, shows Qumra’s appetite for category-leading consumer health platforms with public-sector and enterprise reach. Sensi.AI, focused on care network intelligence, extends the digital health franchise into AI-driven aging and care infrastructure. The portfolio is consistent with the thesis: late-stage, revenue-generating, AI-enabled, and built for global scale.

Stage and check size make Qumra a fit for the round that takes a company from regional traction to global execution. Five-to-twenty-five-million-dollar Qumra checks within rounds of twenty to sixty million place the firm naturally as a Series B or C lead, with growth follow-on capacity. The firm typically takes meaningful ownership and active board involvement. Israeli founders raising in the local market will find Qumra one of the few specialized late-stage options; non-Israeli founders without an Israeli nexus are not the natural fit, since the firm’s mandate concentrates on companies with that origin or significant operating tie. Companies raising small bridges, pre-revenue rounds, or party-round structures are not the audience.

Decision-making sits with a senior partnership in Tel Aviv that has been investing together for nearly a decade. The firm’s deliberate pace, focused portfolio size, and post-investment engagement reflect a model designed for partners to be substantive on every deal. The investment process emphasizes commercial due diligence, customer references, and quantitative analysis of revenue quality, sales efficiency, and capital allocation discipline.

Warm-intro paths run through existing Qumra portfolio CEOs, leading Israeli early-stage venture firms whose Series A graduates are Qumra’s natural pipeline, US and European co-investors with Israeli activity, and the network of operating advisors and customer reference contacts that mature companies build over time. Boutique investment bankers covering Israeli growth-stage technology are a credible route. Cold inbound is unproductive at this stage; the firm engages most readily through trusted founder and investor references.

Founders should approach Qumra when revenue is meaningful, retention is strong, the global expansion plan is concrete, and the round size fits the firm’s check. Approaching at Series A, with thin commercial data, or with a story that depends on near-term clinical validation will not survive diligence. The firm rewards founders who arrive with rigorous commercial metrics, a defined sales motion, and a clear sense of how the next round of capital converts into category leadership. For Israeli digital health and AI healthcare companies in that posture, Qumra is among the most natural late-stage partners in the local market.